The activity of a new ketolide, ABT-773, was compared to the activity of the ketolide telithromycin (HMR-3647) against over 600 gram-positive clinical isolates, including 356 Streptococcus pneumoniae, 167 Staphylococcus aureus, and 136 Streptococcus pyogenes isolates. Macrolide-susceptible isolates as well as macrolide-resistant isolates with ribosomal methylase (Erm), macrolide efflux (Mef), and ribosomal mutations were tested using the NCCLS reference broth microdilution method. Both compounds were extremely active against macrolide-susceptible isolates, with the minimum inhibitory concentrations at which 90% of the isolates tested were inhibited (MIC 90 s) for susceptible streptococci and staphylococci ranging from 0.002 to 0.03 g/ml for ABT-773 and 0.008 to 0.06 g/ml for telithromycin. ABT-773 had increased activities against macrolide-resistant S. pneumoniae (Erm MIC 90 , 0.015 g/ ml; Mef MIC 90 , 0.12 g/ml) compared to those of telithromycin (Erm MIC 90 , 0.12 g/ml; Mef MIC 90 , 1 g/ml). Both compounds were active against strains with rRNA or ribosomal protein mutations (MIC 90 , 0.12 g/ml). ABT-773 was also more active against macrolide-resistant S. pyogenes (ABT-773 Erm MIC 90 , 0.5 g/ml; ABT-773 Mef MIC 90 , 0.12 g/ml; telithromycin Erm MIC 90 , >8 g/ml; telithromycin Mef MIC 90 , 1.0 g/ml). Both compounds lacked activity against constitutive macrolide-resistant Staphylococcus aureus but had good activities against inducibly resistant Staphylococcus aureus (ABT-773 MIC 90 , 0.06 g/ml; telithromycin MIC 90 , 0.5 g/ml). ABT-773 has superior activity against macrolide-resistant streptococci compared to that of telithromycin.
Increasing antimicrobial resistance, particularly in Streptococcus pneumoniae, has increased the need for drugs effective against resistant isolates. ABT-773 (A-195773.0) is a novel compound in the ketolide class with significant advantages over the general antimicrobial profile of macrolide antibiotics. Ketolide antibiotics are extremely active against macrolideresistant streptococci with either low-level (macrolide efflux [Mef] ) or high-level (ribosomal methylase [Erm] ) resistance to macrolides (1) . Ketolides also have excellent in vitro activities against macrolide-resistant organisms with inducible methylase expression, as these compounds appear to be noninducers of methylase (2, 15) . ABT-773 has excellent in vitro potency against macrolide-resistant gram-positive pathogens and has entered phase III clinical trials for the treatment of bacterial upper and lower respiratory tract infections (3) . In this study, the in vitro activities of ABT-773 against macrolideresistant and -susceptible respiratory pathogens are compared to those of telithromycin, another ketolide antibiotic, as well as those of a representative of the macrolide class, erythromycin.
(This work was previously presented in part at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 1999).
MATERIALS AND METHODS
Susceptibility testing. Testing was performed using the broth microdilution method as described by NCCLS (8) . S. pneumoniae and S. pyogenes were tested using Mueller-Hinton broth with 3% lysed horse blood (Becton Dickinson Microbiology Systems, Sparks, Md.). The test medium for Staphylococcus aureus was Mueller-Hinton broth. Quality control was performed according to NCCLS by using S. pneumoniae ATCC 49619 and Staphylococcus aureus ATCC 29213. Incubation was at 35°C for 18 to 24 h in ambient air. Bacterial strains used in this study were clinical isolates collected from 1994 to 2000 in the United States and Europe from several sources, including various surveillance studies and clinical trials.
ABT-773 and telithromycin were synthesized at Abbott Laboratories (Abbott Park, Ill.). Erythromycin, clindamycin, and penicillin were purchased from Sigma Chemical Co. (St. Louis, Mo.).
Resistance determinants. The resistance mechanisms of macrolide-resistant streptococci and staphylococci were determined by PCR using primers specific for known resistance determinants [mef(A), erm(A), erm(B), erm(C), and msr(A)] as previously described (10, 11) . Amplification primers were chosen from sequences deposited in GenBank by using Oligo 5.0 (NBI Software, Plymouth, Minn.) as previously described. The inducible regulation of methylase in Staphylococcus aureus and S. pyogenes was identified by the double disk diffusion test and by susceptibility to clindamycin as previously described (9) . All primers in this study were purchased from Sigma-Genosys (The Woodlands, Tex.).
S. pneumoniae isolates which were negative for known macrolide resistance markers were examined for mutations in 23S rRNA domains II and V and ribosomal proteins L4 and L22 to include regions where mutations associated with macrolide resistance have been previously described in streptococci and other species (6, (12) (13) (14) . Primers for amplification and sequence of the DNA regions that encode the 23S rRNA (rrl) and the ribosomal proteins L4 (rplD) and L22 (rplV) were chosen from publicly available DNA sequences (Streptococcus pneumoniae TIGR4 rDNA, SPSPrrnaD23S6; L4 TIGR4, SP0210; and L22 TIGR4, SPO214) (http://www.tigr.org). Primers used were: 23S rDNA domain V primer set 1 (Escherichia coli numbering) forward primer (bp 1921 to 1938) 5Ј-GGTCCTAAGGTAGCGAAA-3Ј, reverse primer (bp 2163 to 2179) 5Ј-GG GTAGTATCCCAACAG-3Ј; 23S rDNA domain V primer set 2 (E. coli numbering) forward primer (bp 2491 to 2507) 5Ј-TTTGGCACCTCGATGTC-3Ј, reverse primer (bp 2687 to 2704) 5Ј-GGCAAGACAACTGGTACA-3Ј; 23S rDNA domain II (E. coli numbering) forward primer (bp 517 to 534) 5Ј-CGTG TGCCTACAACAAGT-3Ј, reverse primer (bp 823 to 839) 5Ј-ACGCTAGCCC TAAAGCT-3Ј; L4 protein forward primer (bp ϩ37 to ϩ53 [from ATG start]) 5Ј-GAAGCTGGCCAAGTTGT-3Ј, reverse primer (bp ϩ393 to ϩ413 [from ATG start]) 5Ј-TCAGCAGTTTTTGGAGCTGTA-3Ј; and L22 protein forward primer (bp Ϫ133 to Ϫ117 [from ATG start]) 5Ј-GACGTAAACACGTACCT-3Ј, reverse primer (bp ϩ457 to ϩ473 [from ATG start]) 5Ј-CGGATTGCAAGAT CTTC-3Ј. PCR was performed for 40 cycles with the following parameters: 94°C for 15 s, 45°C (for rDNA) or 55°C (for rplD and rplV) for 30 s, and 72°C for 30 s followed by 72°C elongation for 5 min. PCR products were purified using a Quantum Prep Spin Column (Bio-Rad, Hercules, Calif.).
Amplification products were sequenced using the Big Dye sequencing kit (Applied Biosystems Inc., Foster City, Calif.). Sequencing reactions were purified with an Auto-Seq G-50 column (Amersham Pharmacia Biotech, Piscataway, N.J.) and run on an ABI 377 automated sequencer. DNA sequences of amplified products from the macrolide-resistant strains were compared to publicly available sequences of target genes and were found to be highly homologous to those of wild-type strains, with the exception of nucleotide substitutions in regions of previously described mutations, which are discussed in Results. The abovementioned operons (rrl, rplD, and rplV) were also amplified from S. pneumoniae ATCC 49619, a macrolide-susceptible strain, and sequenced for comparison as wild-type controls.
Ribosome binding studies. Ribosomes were purified from the S. pneumoniae macrolide-susceptible strain ATCC 49619. Mid-log phase (optical density at 600 nm, ϳ0.3 to 0.4) cells were collected by centrifugation and washed twice with high salt buffer (10 mM Tris-HCl [pH 7.5], 1 M NH 4 Cl, 15 mM Mg(AcO) 2 , 50 mM KCl, 6 mM ␤-mercaptoethanol) followed by a single wash with low-salt buffer (10 mM Tris-HCl [pH 7.5], 60 mM NH 4 Cl, 15 mM Mg(AcO) 2 , 50 mM KCl, 6 mM ␤-mercaptoethanol). After the final wash, the cells were frozen on EtOH-dry ice and stored at Ϫ80°C until further processing. Cells were thawed and broken by two passes of French press at 12,000 lb/in 2 . The crude lysate was centrifuged at 30,000 ϫ g for 40 min. The pellet was discarded and the clear portion of the supernatant was centrifuged again at 100,000 ϫ g for 2 h. Phenylmethylsulfonyl fluoride (1 mM) (Sigma Chemical Co.) and RNase inhibitor (Prime RNase inhibitor; Brinkmann Instruments, Westbury, N.Y.) were added prior to cell lysis. The pellet from the final centrifugation (ribosome fraction) was resuspended in ribosome binding buffer ( 
RESULTS
ABT-773 was generally one to two twofold dilutions more active than telithromycin against macrolide-susceptible streptococci, with ABT-773 at MIC 90 s of 0.002 and Յ0.002 g/ml for S. pneumoniae and S. pyogenes, respectively, versus telithromycin at MIC 90 s of 0.008 and 0.015 g/ml, respectively (Table  1 ; also see Table 3 ).
The improved activity of ABT-773 compared to that of telithromycin was more evident when examining the MICs of the compounds for macrolide-resistant pneumococci, particularly strains with Mef ( Table 1 ). The ABT-773 MIC 90 for S. pneumoniae with Mef(A) is 0.12 g/ml, three twofold dilutions lower than the telithromycin MIC 90 of 1.0 g/ml. The MIC 90 of erythromycin for efflux strains is 8.0 g/ml. Both compounds have excellent activity against S. pneumoniae strains producing Erm(B) methylase, with telithromycin having a fourfold-higher MIC 90 than ABT-773 (the MIC 90 of ABT-773 is 0.015 g/ml; the MIC 90 of telithromycin is 0.12 g/ml; the MIC 90 of erythromycin is Ͼ32 g/ml). Approximately 5% of macrolide-resistant strains in the United States produce both Mef(A) and Erm(B) (7, 10) . The MICs of ABT-773 and telithromycin for 39 clinical isolates of S. pneumoniae with both erm(B) and mef(A) were determined. The MIC 90 for both ketolides was 0.25 g/ml, indicating that against strains with both mechanisms, the activities of ABT-773 and telithromycin are similar to those observed against strains with efflux only.
The susceptible, Mef, and Erm S. pneumoniae strains in Table 1 were also categorized by penicillin susceptibility ( Table  2 ). The activities of both ketolides indicate that they are unaffected by penicillin susceptibility, although the MIC 90 values (Table 1 ). The DNA sequences of rrl, rplD, and rplV encoding 23S rRNA (only domain II and domain V regions were studied) and the ribosomal proteins L4 and L22, respectively, were compared to those of macrolidesusceptible strains. All 19 strains were found to contain mutations either in domain V of 23S rDNA or in L4. These mutations had been previously observed to be associated with macrolide-lincosamide-streptogramin B resistance (6, 12, 13) . Ribosomal mutations have been recently described as a rare cause of clinical macrolide resistance in S. pneumoniae (5, 12) . No mutations in domain II or L22 were observed. The majority (n ϭ 17) of the isolates in this study had mutations in domain V of the 23S rDNA, A2059G (E. coli numbering system) being the most common (14 of 17). Two isolates having a base change at 2611 (C3T) and one at 2058 (A3G) were also identified. Two isolates had multiple amino acid substitutions in the L4 ribosomal protein, including amino acid substitutions of 69 GTG 71 to TPS, previously described as being associated with macrolide resistance in S. pneumoniae (12, 13) . These two L4 mutants had no changes in their 23S rDNA sequences. The activities of the two ketolides and erythromycin were examined against these strains to determine the effect of ribosome mutation on the activities of the ketolides. Although these isolates had differing susceptibilities to erythromycin and clindamycin, all isolates had ketolide MICs of 1 g/ml or less (MIC 90 s of 0.12 g/ml for ABT-773 and telithromycin). These data suggest that mutations in streptococcal rRNA or ribosomal proteins, most likely selected by macrolide exposure, do not typically result in resistance to ketolides.
In order to examine the differences between the two ketolides and erythromycin at the ribosomal level, the binding affinities of the compounds to susceptible S. pneumoniae ribosomes were examined. As shown in Fig. 1 , the IC 50 of erythromycin is 566 nM, the IC 50 of telithromycin is 120 nM, and the IC 50 of ABT-773 is 52.7 nM. The experiments were repeated at least twice for each competition assay; the results were reproducible. The differences in IC 50 between the compounds correlate well with the overall in vitro activities, with ABT-773 having over a twofold increased affinity for ribosomal binding compared to that of telithromycin and a tenfold improvement compared to that erythromycin.
ABT-773 is also extremely active against macrolide-resistant S. pyogenes (Table 3 ). The compound is more potent than telithromycin against strains with Mef or with constitutive Erm(B) methylase (ABT-773 Mef and Erm MIC 90 s, 0.12 and 0.5 g/ml, respectively; telithromycin Mef and Erm MIC 90 s, 1.0 and Ͼ8.0 g/ml, respectively). The ketolides are also very potent against strains with inducibly regulated erm(A), with MIC 90 s of 0.002 g/ml and 0.015 g/ml for ABT-773 and telithromycin, respectively.
The ketolides are active against Staphylococcus aureus strains that are macrolide susceptible, as shown in Table 4 , with MIC 90 s of 0.03 g/ml and 0.06 g/ml for ABT-773 and telithromycin, respectively, but lack activity against strains with constitutive production of Erm(A) or Erm(C) methylase. However, due to the apparent inability of ketolides to act as inducers for methylase production, they maintain good in vitro activity against strains with inducible methylase (ABT-773 MIC 90 , 0.06 g/ml; telithromycin MIC 90 , 0.5 g/ml) (2).
DISCUSSION
The ketolide class of antibiotics has been shown to be extremely potent against both susceptible and resistant streptococci. The activity of this class is reflected in the excellent in vitro potency of ABT-773 against macrolide-resistant strepto- The control is the sample without a competitor drug, which gave an approximately 1,000 dpm count. (7, 10) . The ABT-773 MICs for 19 clinical isolates with rRNA or protein mutations were Յ1 g/ml, suggesting ribosomal mutation alone is not likely to result in a substantial decrease in in vitro activity. The affinity of ABT-773 for S. pneumoniae ribosomes is twofold higher than that of telithromycin and tenfold higher than that of erythromycin, suggesting that increased binding affinity for the ribosome is at least partially responsible for the increased potency. Capobianco et al. previously showed that ABT-773 had a rapid association with the ribosome and a very slow dissociation compared to those of erythromycin (4) .
The enhanced activity of ABT-773 against macrolide resistant streptococci is most evident with S. pyogenes. The MIC 90 of ABT-773 is three to four twofold dilutions lower than that of telithromycin against strains with efflux or methylase. As the MIC of ABT-773 for these strains does not typically exceed 1.0 g/ml, this drug may be clinically effective against high-level macrolide-resistant group A streptococci.
Although both drugs have good in vitro activity against susceptible staphylococci, they lack activity against Staphylococcus aureus with high-level constitutive macrolide resistance (erythromycin and clindamycin MICs Ͼ 128 g/ml). However, the apparent inability of ketolides to induce expression of methylase allows excellent in vitro activity (ABT-773 MIC 90 , 0.06 g/ml) against strains with inducible methylase production. Clinical efficacy against strains with inducible methylase has yet to be determined.
In summary, the excellent in vitro activity of ABT-773 against macrolide-susceptible and -resistant gram-positive cocci suggests that this compound may be very useful in the treatment of respiratory infections caused by these pathogens, particularly since streptococci for which ABT-773 MICs are Ͼ1 g/ml are extremely rare (Ͻ0.1%) (3) . Clinical treatment trials are presently under way to determine the safety and efficacy of this compound. 
